vs
Artisan Partners Asset Management Inc.（APAM）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
Artisan Partners Asset Management Inc.的季度营收约是Pacira BioSciences, Inc.的1.9倍（$335.5M vs $177.4M），Artisan Partners Asset Management Inc.净利率更高（35.2% vs 1.6%，领先33.6%），Artisan Partners Asset Management Inc.同比增速更快（12.9% vs 5.0%），过去两年Artisan Partners Asset Management Inc.的营收复合增速更高（12.7% vs -0.2%）
阿蒂森伙伴资产管理公司（Artisan Partners）是总部位于美国威斯康星州密尔沃基的资产管理机构，除美国本土外，还在都柏林、香港、伦敦、新加坡、悉尼设有办公室，为全球客户提供专业的资产管理服务。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
APAM vs PCRX — 直观对比
营收规模更大
APAM
是对方的1.9倍
$177.4M
营收增速更快
APAM
高出7.9%
5.0%
净利率更高
APAM
高出33.6%
1.6%
两年增速更快
APAM
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $335.5M | $177.4M |
| 净利润 | $118.1M | $2.9M |
| 毛利率 | — | — |
| 营业利润率 | 39.2% | 3.9% |
| 净利率 | 35.2% | 1.6% |
| 营收同比 | 12.9% | 5.0% |
| 净利润同比 | 34.9% | — |
| 每股收益（稀释后） | $1.36 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APAMPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $335.5M | $196.9M | ||
| Q3 25 | $301.3M | $179.5M | ||
| Q2 25 | $282.7M | $181.1M | ||
| Q1 25 | $277.1M | $168.9M | ||
| Q4 24 | $297.1M | $187.3M | ||
| Q3 24 | $279.6M | $168.6M | ||
| Q2 24 | $270.8M | $178.0M |
净利润APAMPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | $118.1M | — | ||
| Q3 25 | $66.8M | $5.4M | ||
| Q2 25 | $67.6M | $-4.8M | ||
| Q1 25 | $61.1M | $4.8M | ||
| Q4 24 | $87.5M | — | ||
| Q3 24 | $73.0M | $-143.5M | ||
| Q2 24 | $57.6M | $18.9M |
毛利率APAMPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
营业利润率APAMPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 39.2% | 1.2% | ||
| Q3 25 | 33.8% | 3.5% | ||
| Q2 25 | 28.2% | 4.7% | ||
| Q1 25 | 31.2% | 1.2% | ||
| Q4 24 | 36.7% | 13.2% | ||
| Q3 24 | 33.3% | -82.8% | ||
| Q2 24 | 32.0% | 15.9% |
净利率APAMPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | 35.2% | — | ||
| Q3 25 | 22.2% | 3.0% | ||
| Q2 25 | 23.9% | -2.7% | ||
| Q1 25 | 22.1% | 2.8% | ||
| Q4 24 | 29.5% | — | ||
| Q3 24 | 26.1% | -85.1% | ||
| Q2 24 | 21.3% | 10.6% |
每股收益（稀释后）APAMPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $1.36 | $0.05 | ||
| Q3 25 | $0.93 | $0.12 | ||
| Q2 25 | $0.94 | $-0.11 | ||
| Q1 25 | $0.82 | $0.10 | ||
| Q4 24 | $0.99 | $0.38 | ||
| Q3 24 | $1.03 | $-3.11 | ||
| Q2 24 | $0.80 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $144.3M |
| 总债务越低越好 | $190.0M | — |
| 股东权益账面价值 | $438.8M | $653.9M |
| 总资产 | $1.6B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
现金及短期投资APAMPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
总债务APAMPCRX
| Q1 26 | — | — | ||
| Q4 25 | $190.0M | $372.2M | ||
| Q3 25 | $190.0M | $376.7M | ||
| Q2 25 | $200.0M | $580.5M | ||
| Q1 25 | $200.0M | $583.4M | ||
| Q4 24 | $200.0M | $585.3M | ||
| Q3 24 | $200.0M | — | ||
| Q2 24 | $200.0M | — |
股东权益APAMPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $438.8M | $693.1M | ||
| Q3 25 | $402.1M | $727.2M | ||
| Q2 25 | $381.8M | $757.8M | ||
| Q1 25 | $356.5M | $798.5M | ||
| Q4 24 | $388.9M | $778.3M | ||
| Q3 24 | $372.1M | $749.6M | ||
| Q2 24 | $341.2M | $879.3M |
总资产APAMPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.6B | $1.3B | ||
| Q2 25 | $1.4B | $1.5B | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B |
负债/权益比APAMPCRX
| Q1 26 | — | — | ||
| Q4 25 | 0.43× | 0.54× | ||
| Q3 25 | 0.47× | 0.52× | ||
| Q2 25 | 0.52× | 0.77× | ||
| Q1 25 | 0.56× | 0.73× | ||
| Q4 24 | 0.51× | 0.75× | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.59× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $172.0M | — |
| 自由现金流经营现金流 - 资本支出 | $171.6M | — |
| 自由现金流率自由现金流/营收 | 51.2% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | 1.46× | — |
| 过去12个月自由现金流最近4个季度 | $420.6M | — |
8季度趋势，按日历期对齐
经营现金流APAMPCRX
| Q1 26 | — | — | ||
| Q4 25 | $172.0M | $43.7M | ||
| Q3 25 | $40.4M | $60.8M | ||
| Q2 25 | $50.9M | $12.0M | ||
| Q1 25 | $157.9M | $35.5M | ||
| Q4 24 | $372.8M | $33.1M | ||
| Q3 24 | $112.8M | $53.9M | ||
| Q2 24 | $75.9M | $53.2M |
自由现金流APAMPCRX
| Q1 26 | — | — | ||
| Q4 25 | $171.6M | $43.5M | ||
| Q3 25 | $40.4M | $57.0M | ||
| Q2 25 | $50.9M | $9.3M | ||
| Q1 25 | $157.7M | $26.9M | ||
| Q4 24 | $371.3M | $31.0M | ||
| Q3 24 | $112.4M | $49.8M | ||
| Q2 24 | $75.2M | $51.6M |
自由现金流率APAMPCRX
| Q1 26 | — | — | ||
| Q4 25 | 51.2% | 22.1% | ||
| Q3 25 | 13.4% | 31.7% | ||
| Q2 25 | 18.0% | 5.1% | ||
| Q1 25 | 56.9% | 15.9% | ||
| Q4 24 | 125.0% | 16.6% | ||
| Q3 24 | 40.2% | 29.6% | ||
| Q2 24 | 27.8% | 29.0% |
资本支出强度APAMPCRX
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.1% | 5.1% | ||
| Q4 24 | 0.5% | 1.1% | ||
| Q3 24 | 0.1% | 2.4% | ||
| Q2 24 | 0.2% | 0.9% |
现金转化率APAMPCRX
| Q1 26 | — | — | ||
| Q4 25 | 1.46× | — | ||
| Q3 25 | 0.60× | 11.20× | ||
| Q2 25 | 0.75× | — | ||
| Q1 25 | 2.58× | 7.37× | ||
| Q4 24 | 4.26× | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 1.32× | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APAM
暂无分部数据
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
